VIRBAC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 360 EUR | 0.00% |
|
+0.14% | +0.14% |
| Apr. 02 | Virbac: 'strategic' acquisition of Sasaeah in Japan | CF |
| Apr. 01 | Virbac SA acquired Sasaea Holdings Co., Ltd. from ORIX Corporation. | CI |
| Sales 2023 | 1.25B 1.32B | Sales 2024 * | 1.38B 1.47B | Capitalization | 3.01B 3.2B |
|---|---|---|---|---|---|
| Net income 2023 | 121M 129M | Net income 2024 * | 139M 148M | EV / Sales 2023 | 2.43 x |
| Net cash position 2023 * | 118M 125M | Net Debt 2024 * | 137M 146M | EV / Sales 2024 * | 2.28 x |
| P/E ratio 2023 |
25
x | P/E ratio 2024 * |
21.8
x | Employees | 5,459 |
| Yield 2023 * |
0.45% | Yield 2024 * |
0.4% | Free-Float | 49.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Virbac
More press releases
More news
| 1 week | +0.14% | ||
| Current month | +4.05% | ||
| 1 month | +6.51% | ||
| 3 months | +3.75% | ||
| 6 months | +38.20% | ||
| Current year | +0.14% |
1 week
350.50
372.50
1 month
316.50372.50
Current year
316.50372.50
1 year
232.50372.50
3 years
215.00448.50
5 years
132.20448.50
10 years
102.10448.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 10-12-31 | |
Philippe Capron
BRD | Director/Board Member | 64 | 03-12-31 |
| Chairman | 59 | 97-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 1 M€ | -.--% | ||
| 0.02% | 773 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 360 | 0.00% | 2 996 |
| 24-04-15 | 360 | -1.37% | 2,616 |
| 24-04-12 | 365 | +1.67% | 6,919 |
| 24-04-11 | 359 | +2.13% | 2,535 |
| 24-04-10 | 351.5 | -2.23% | 2,896 |
Real-time Euronext Paris, April 16, 2024 at 11:35 am EDT
More quotes
Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families:
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).
Sector
Pharmaceuticals
Calendar
2024-04-15
- Q1 2024 Sales and Revenue Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
360
EUR
Average target price
358.4
EUR
Spread / Average Target
-0.45%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.14% | 3.2B | |
| -22.49% | 68.44B | |
| -7.11% | 6.84B | |
| +15.25% | 3.42B | |
| -17.08% | 1.34B | |
| -5.66% | 1.22B | |
| -28.25% | 1.2B | |
| -13.40% | 1.14B | |
| -3.66% | 1.01B | |
| +1.30% | 897M |
- Stock Market
- Equities
- VIRP Stock
